Erythromycin-Lect
Erythromycin-LekT: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Erythromycin-LekT
ATX code: J01FA01
Active ingredient: erythromycin (Erythromycin)
Producer: JSC Tyumen Chemical-Pharmaceutical Plant (Russia)
Description and photo update: 2020-18-04
Prices in pharmacies: from 65 rubles.
Buy
Erythromycin-LekT is an antibacterial drug of the macrolide group that has a bacteriostatic effect.
Release form and composition
The drug is produced in the form of tablets covered with an enteric film: white or grayish-white, round, biconvex, the core at a break in white or white with a yellow tint (20 pcs. In orange glass jars, in a cardboard box 1 can; 10 pcs in blisters, in a cardboard box 1 or 2. Each pack also contains instructions for the use of Erythromycin-LekT).
1 tablet contains:
- active substance: erythromycin - 250 mg;
- auxiliary components: potato starch, polysorbate-80, povidone, calcium stearate;
- composition of the film shell: castor bean seed oil, macrogol-6000, acetylphthalyl cellulose, titanium dioxide.
Pharmacological properties
Pharmacodynamics
The active component of Erythromycin-LekT is erythromycin, the first antibiotic of the macrolide class, which has a bacteriostatic effect. The broad spectrum of activity of the drug is due to its property of binding to the 50S subunit of ribosomes, which leads to disruption of the formation of peptide compounds between amino acid molecules and blocking the synthesis of proteins of microorganisms. Erythromycin does not affect the synthesis of nucleic acids. High doses can act bactericidal against some types of pathogen.
The following microbes are susceptible to Erythromycin-LekT:
- gram-positive microorganisms: Streptococcus spp. (speciales) including Streptococcus spp. groups viridans, Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus spp. (producing and non-producing penicillinase), including Staphylococcus aureus (excluding methicillin-resistant strains), Corynebacterium minutissimum, Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis;
- gram-negative microorganisms: Campylobacter jejuni, Bordetella pertussis, Legionella spp. (including Legionella pneumophila), Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae, Haemophilus influenzae;
- other microorganisms: Treponema spp., Chlamydia spp. (including Chlamydia trachomatis), Mycoplasma spp. (including Mycoplasma pneumoniae), Ureaplasma urealyticum, Entamoeba histolytica, Propionibacterium acnes.
Microorganisms are considered sensitive if their growth slows down when the concentration of erythromycin in the blood plasma is less than 0.5 mg / l, moderately sensitive - 1-6 mg / l, stable - more than 6 mg / l.
Resistance to erythromycin is shown by gram-negative bacilli, including microorganisms such as Escherichia coli, Salmonella spp., Proteus spp., Klebsiella spp., Shigella spp. and other members of the family Enterobacteriaceae, Acinetobacter spp., Pseudomonas aeruginosa, non-fermenting bacteria. In addition, anaerobic bacteria (Bacteroides spp., Including Bacteroides fragilis), methicillin-resistant strains of Staphylococcus aureus, enterococci Enterococcus spp., Microbacteria are resistant to Erythromycin-LekT.
Erythromycin, being an agonist of motilin receptors, has prokinetic properties. Its action helps to increase the amplitude of contraction of the pylorus and to improve antral-duodenal coordination, which leads to an acceleration of the evacuation of stomach contents.
Pharmacokinetics
After oral administration, erythromycin is well absorbed in the gastrointestinal tract. The bioavailability of the substance is 30–65%. The maximum concentration in blood plasma is reached after 2-4 hours. Simultaneous food intake does not affect the degree of absorption.
Plasma protein binding - from 70 to 90%.
The distribution of erythromycin in the body is uneven. A large amount of it accumulates in the liver, spleen, kidneys. The concentration level in urine and bile is tens of times higher than the content of the active substance in plasma. It penetrates well into the pleural cavity, lung tissue, lymph nodes, ascitic and synovial fluid, middle ear exudate, sperm, prostate secretions. In breast milk, up to 50% of the plasma concentration is found. It overcomes the placental barrier, in the fetal blood its content can reach up to 20% of the content in the mother's plasma. It penetrates the blood-brain barrier poorly. In cerebrospinal fluid, the concentration of erythromycin is 10% of the plasma level. The permeability of the meninges for erythromycin increases slightly with inflammation.
More than 90% of the dose taken is metabolized in the liver, including with partial formation of inactive metabolites. Erythromycin inhibits liver microsomal enzymes CYP3A4, CYP3A5 and CYP3A7, which are involved in its biotransformation.
The half-life (T 1/2) is 1.4-2 hours, with anuria - 4-6 hours. It is excreted unchanged with bile - 20-30%, with urine - 2-5%.
Indications for use
- treatment of infectious and inflammatory diseases caused by microorganisms sensitive to erythromycin: diphtheria (including the carriage of the pathogen); brucellosis; trachoma; legionellosis (legionnaires' disease); listeriosis; erythrasma; scarlet fever; gonorrhea; amoebic dysentery; respiratory tract infections (tracheitis, bronchitis, pneumonia); otorhinolaryngological infections (tonsillitis, sinusitis, otitis media); whooping cough (including prevention); infections of the bile ducts (cholecystitis); infectious pathologies of the skin and soft tissues (infected wounds, bedsores, trophic ulcers, burns of the II – III degree, pustular skin diseases, including juvenile acne); infections of the mucous membrane of the eyes;
- treatment of urinary infections in pregnant women caused by Chlamydia trachomatis; uncomplicated chlamydia (with localization in the lower urogenital tract and rectum) in adults with tetracyclines intolerance or ineffectiveness;
- prevention of infectious complications during medical and diagnostic procedures (including preoperative bowel preparation, endoscopy, dental interventions, patients with heart defects);
- prevention of exacerbations of streptococcal infection (pharyngitis, tonsillitis) in patients with rheumatism.
Contraindications
Absolute:
- significant hearing loss;
- concomitant therapy with terfenadine, pimozide, cisapride, astemizole;
- lactation period;
- age up to 14 years;
- hypersensitivity to other macrolides or drug components.
Erythromycin-LekT 250 mg tablets should be used with caution in case of hepatic and / or renal failure, an increase in the duration of the ventricular complex (prolongation of the QT interval) on an electrocardiogram (ECG), a history of arrhythmias, a history of jaundice, during pregnancy and in old age.
Erythromycin-LekT, instructions for use: method and dosage
Erythromycin-LekT tablets are taken orally, swallowed whole (without violating the integrity of the film membrane) and washed down with water, 1-2 hours before meals or 2-3 hours after meals.
It is forbidden to drink the tablets with milk or dairy products.
The dose and duration of therapy is prescribed by the doctor individually, taking into account the age, body weight of the patient and the severity of the infectious disease.
For adults, a single dose of Erythromycin-LekT can range from 0.25 g to 0.5 g, the maximum daily dose is 4 g.
Recommended dosage of Erythromycin-Lect for adults:
- treatment of primary syphilis: course dose - 30-40 g, course duration - from 10 to 15 days;
- amoebic dysentery: 0.25 g 4 times a day (every 6 hours) for 10-14 days;
- legionellosis: 0.5-1 g 4 times a day, duration of treatment - 14 days;
- gonorrhea: during the first three days - 0.5 g 4 times a day, then within 7 days - 0.25 g 4 times a day;
- gastroparesis (it is preferable to use erythromycin for intravenous administration): 0.5 hours before meals - 0.15-0.25 g 3 times a day;
- scarlet fever: the doctor sets the dose individually, the course of treatment is 10 days or more;
- listeriosis: 0.25-0.5 g 4 times a day for at least 7 days. At normal body temperature, etiotropic therapy should be continued for 7 days, with severe forms of listeriosis - from 14 to 21 days;
- erythrasma (as part of complex therapy with external agents): 0.25 g 4 times a day for 5-7 days;
- preoperative prevention of intestinal infectious complications: 1 g 3 times - 19 hours, 18 hours and 9 hours before the start of the surgical intervention;
- prevention of streptococcal infection with tonsillitis, pharyngitis: at the rate of 0.02–0.05 g per 1 kg (g / kg) of body weight, divided into 2–4 doses, the duration of the course of treatment is at least 10 days;
- prevention of septic endocarditis in patients with heart defects: 1 hour before a medical or diagnostic procedure - 1 g, then 0.5 g again after 6 hours;
- whooping cough: 0.04–0.05 g / kg of the patient's body weight, divided into 2–4 doses, the duration of therapy is 5–14 days;
- genitourinary infections during pregnancy: 0.5 g 4 times a day for 7 days. With poor tolerance of Erythromycin-LekT, it is allowed to reduce a single dose to 0.25 g and simultaneously extend the course of treatment to at least 14 days;
- uncomplicated chlamydia in patients with tetracyclines intolerance: 0.5 g 4 times a day for at least 7 days.
For the treatment of patients aged 14 to 18 years, it is recommended to use erythromycin in a daily dose of 0.03–0.05 g / kg of body weight, divided into 2–4 doses. If necessary, the relief of severe infections, the dose can be doubled.
Recommended dosage of Erythromycin-LekT for children and adolescents 14-18 years old:
- diphtheria carriage (treatment): 0.25 g 2 times a day;
- prevention of streptococcal infection in tonsillitis, pharyngitis: 0.02–0.03 g / kg of body weight, divided into 2–4 doses. The duration of therapy is at least 10 days;
- prevention of septic endocarditis in patients with heart defects: 1 hour before a medical or diagnostic procedure - at a dose of 0.02 g / kg of body weight, then 0.01 g / kg, again after 6 hours.
Side effects
- from the cardiovascular system: tachycardia, prolongation of the QT interval on the ECG, in patients with an extended QT interval - atrial fibrillation and / or atrial flutter;
- from the digestive system: abdominal pain, nausea, vomiting, diarrhea, dysbiosis, oral candidiasis, gastralgia, tenesmus, pseudomembranous colitis, pancreatitis, cholestatic jaundice, liver dysfunction, increased liver transaminase activity;
- on the part of the organ of hearing: tinnitus, hearing loss;
- allergic reactions: skin rash, urticaria, eosinophilia, anaphylactic shock.
Overdose
Symptoms: hearing loss, liver dysfunction, including acute liver failure.
Treatment: immediate intake of activated carbon. Gastric lavage is advisable only in cases where the overdose exceeds the average therapeutic dose by 5 times. Ensure careful control over the state of the respiratory system, acid-base state and electrolyte metabolism. Shows an ECG, if necessary - artificial ventilation.
The use of forced diuresis, hemodialysis or peritoneal dialysis is ineffective.
special instructions
If the patient is on concomitant therapy with other drugs, then when prescribing Erythromycin-LekT, he must inform the doctor about it. This will avoid any negative pharmacological interactions.
Long-term use of Erythromycin-LekT must be accompanied by careful monitoring of laboratory parameters of liver function. It should be borne in mind that after 7-14 days of continuous therapy, the risk of cholestatic jaundice increases, although its symptoms can be observed as early as a few days after the start of taking the pills.
It is recommended to prescribe Erythromycin-LekT with caution to elderly patients or with renal and / or hepatic insufficiency due to the fact that this category of patients is highly likely to develop an ototoxic effect.
Tinnitus and / or hearing loss occurs when high doses of erythromycin are used, usually these side effects are reversible.
Taking Erythromycin-LekT can distort the results of analyzes when determining the content of catecholamines in urine and studies by colorimetric determination of hepatic transaminase activity in the blood using diphenylhydrazine.
Influence on the ability to drive vehicles and complex mechanisms
The use of Erythromycin-LekT does not adversely affect the patient's ability to drive vehicles or complex mechanisms, however, it is recommended to be especially careful when performing potentially hazardous activities during the treatment period.
Application during pregnancy and lactation
The use of Erythromycin-LekT during lactation is contraindicated.
With caution, only in cases where the expected therapeutic effect for the mother exceeds the potential threat to the fetus, it is allowed to prescribe the drug during pregnancy.
Pediatric use
The use of Erythromycin-LekT for the treatment of children under the age of 14 is contraindicated.
With impaired renal function
Erythromycin-LekT should be used with caution in patients with renal insufficiency.
For violations of liver function
Erythromycin-LekT should be used with caution in patients with hepatic impairment.
Use in the elderly
It is recommended to use Erythromycin-LekT with caution in old age due to the increased likelihood of developing an ototoxic effect.
Drug interactions
With simultaneous use with Erythromycin-LekT:
- lincomycin, clindamycin, chloramphenicol: a combination with each of these agents causes antagonism;
- cephalosporins, penicillins, carbapenems: the bactericidal activity of beta-lactam antibiotics decreases;
- theophylline: erythromycin increases its concentration;
- cyclosporine: increased nephrotoxicity of cyclosporine, especially with concomitant renal failure;
- triazolam, midazolam: their clearance decreases, which can lead to increased pharmacological effects;
- methylprednisolone, felodipine, coumarin anticoagulants: elimination slows down and the effect of these funds increases;
- hormonal contraceptives: a decrease in the effectiveness of hormonal contraceptives should be considered;
- digoxin: erythromycin increases its bioavailability;
- lovastatin, simvastatin and other statins: the combination with these drugs increases the likelihood of an increased risk of rhabdomyolysis;
- tubular secretion blockers: help to lengthen the half-life of erythromycin;
- carbamazepine, hexobarbital, phenytoin, valproic acid, alfentanil, lovastatin, bromocriptine, disopyramide: the plasma levels of these drugs may increase;
- terfenadine, astemizole: concomitant therapy with each of these agents can cause flickering and flutter of the ventricles, ventricular tachycardia, including fatal arrhythmias;
- dihydroergotamine, non-hydrogenated ergot alkaloids: it should be borne in mind that the combination with ergot alkaloids causes vasoconstriction to complete spasm, dysesthesia;
- sulfonamides: combination therapy with sulfonamides increases the sensitivity to erythromycin of some resistant strains of Haemophilus influenzae.
Analogs
Analogs of Erythromycin-LekT are Bacticap, Vilprafen, Zimbaktar, Klabaks, Clarithromycin, Macropen, Roxithromycin, Erythromycin (tablets, lyophilisate for intravenous administration, ointment for external use, eye ointment), etc.
Terms and conditions of storage
Keep out of the reach of children.
Store at temperatures up to 25 ° C in a dark place.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Erythromycin-LekT
Reviews about Erythromycin-LekT are positive. Many patients note its high efficiency in the treatment of a number of infectious diseases. In some cases, the antibiotic was used without concomitant probiotic therapy and did not cause digestive side effects. The popularity of the drug is added by the absence of other adverse reactions and the cost, which most patients call affordable.
Price for Erythromycin-Lect in pharmacies
The price of Erythromycin-Lect 250 mg can range from 71 rubles. per pack containing 20 enteric film coated tablets.
Erythromycin-Lect: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Erythromycin-LekT 250 mg enteric-coated tablets 20 pcs. RUB 65 Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
